Nurix Therapeutics Files Q1 2025 10-Q

Ticker: NRIX · Form: 10-Q · Filed: Apr 8, 2025 · CIK: 1549595

Sentiment: neutral

Topics: 10-Q, quarterly-report, biotech

TL;DR

Nurix Q1 2025 10-Q filed. Financials and ops update.

AI Summary

Nurix Therapeutics, Inc. filed a 10-Q for the period ending February 28, 2025. The filing covers the first quarter of their fiscal year. Key financial data and operational details for this period are presented, including comparative figures from the prior year's quarter.

Why It Matters

This filing provides investors with an update on Nurix's financial health and operational progress during the first quarter of fiscal year 2025, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Nurix Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the specific reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is the quarter ended February 28, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on April 8, 2025.

What is Nurix Therapeutics, Inc.'s fiscal year end?

Nurix Therapeutics, Inc.'s fiscal year ends on November 30.

What was the start date of the comparable prior year period?

The start date of the comparable prior year period was December 1, 2023.

What is the Standard Industrial Classification (SIC) code for Nurix Therapeutics, Inc.?

The SIC code for Nurix Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on April 8, 2025 regarding Nurix Therapeutics, Inc. (NRIX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing